-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Psoralen
Category | Human immunodeficiency Virus (HIV) |
CAS | 66-97-7 |
Description | Psoralen is a photoactive probe that has been used to investigate nucleic acid structure and function. It intercalates into DNA and, when activated by ultraviolet radiation, can create covalent interstrand crosslinks, inducing apoptosis. |
Product Information
Synonyms | Ficusin; Furocoumarin |
IUPAC Name | furo[3,2-g]chromen-7-one |
Molecular Weight | 186.16 |
Molecular Formula | C11H6O3 |
Canonical SMILES | C1=CC(=O)OC2=CC3=C(C=CO3)C=C21 |
InChI | InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H |
InChIKey | ZCCUUQDIBDJBTK-UHFFFAOYSA-N |
Boiling Point | 362.00to363.00°C.at760.00mmHg |
Melting Point | 159-164°C. |
Flash Point | 173.1±23.7 °C |
Purity | 97 %. (HPLC). |
Density | 1.389 g/cm3 |
Solubility | Chloroform, slightly in ethanol and ether, practically not in water |
Appearance | Solid powder |
Shelf Life | Stable under recommended storage conditions |
Storage | Store at +4 °C, in dark place. |
Complexity | 284 |
Exact Mass | 186.031694049 |
Index Of Refraction | 1.667 |
In Vitro | Psoralen was able to inhibit the growth of SMMC-7721 cells in a dose- and time-dependent manner and had a strong proapoptotic effect on these cells. It show a dose-dependent increase in caspase-3 activity, and elevated levels of p53 and Bax proteins in psoralen-treated cells, that coincided with dose-dependent decrease in Bcl-2 expression. |
In Vivo | The acute oral median lethal dose of psoralen in ICR mice was determined to be 1,673 mg/kg. C57BL/6 mice were administered psoralen intragastrically at doses of 400 mg/kg or 800 mg/kg, and were sacrificed 24 h after treatment. Changes in various hepatotoxicity indicators demonstrated that psoralen can cause mild liver injury in mice. Psoralen inhibited the viability of normal human liver L02 cells in vitro by inducing S-phase arrest. In addition, psoralen in both the mouse livers and L02 cells upregulated cyclin E1 and p27 protein levels. The 2/3 partial hepatectomy mouse model was used to further explore the effects of psoralen on the liver regeneration and hepatocellular cycle arrest in vivo. The results showed that the decrease of liver regenerative and self-healing capabilities induced by hepatocellular cycle arrest may play an important role in the hepatotoxicity of psoralen. The further mechanism researches indicated that psoralen-induced hepatotoxicity was associated with inhibition of mTOR signalling pathway and mitochondrial injury; furthermore, MHY, an mTOR activator, partly alleviated the inhibition of mTOR and S-phase cycle arrest induced by psoralen in L02 cells. |
PSA | 43.35000 |
Target | Apoptosis; HIV; Influenza Virus |
Vapor Pressure | 5.4X10-6 mm Hg at 25 °C (est) |
XLogP3-AA | 2.3 |